Bellevue Life Sciences Acquisition Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLAC research report →
Companywww.bellevuespac.com
Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry.
- CEO
- Kuk Hyoun Hwang
- IPO
- 2023
- HQ
- Bellevue, WA, US
Price Chart
Valuation
- Market Cap
- $6.98M
- P/E
- -0.17
- P/S
- 4.92
- P/B
- 0.02
- EV/EBITDA
- -1.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -70.05%
- Op Margin
- -726.07%
- Net Margin
- -525.08%
- ROE
- -15.90%
- ROIC
- -11.75%
Growth & Income
- Revenue
- $2.91M · 0.00%
- Net Income
- $-28,888,361 · -1098.19%
- EPS
- $0.00 · 100.00%
- Op Income
- $-18,336,004
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $13.40
- 52W Low
- $3.01
- 50D MA
- $10.74
- 200D MA
- $10.87
- Beta
- 0.53
- Avg Volume
- 15.26K
Get TickerSpark's AI analysis on BLAC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BLAC Coverage
We haven't published any research on BLAC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLAC Report →